- Home
- PESI vs SKYE Comparison
PESI vs SKYE Comparison
Compare PESI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- SKYE
- Stock Information
- Founded
- PESI 1990
- SKYE 2012
- Country
- PESI United States
- SKYE United States
- Employees
- PESI N/A
- SKYE N/A
- Industry
- PESI Environmental Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- SKYE Health Care
- Exchange
- PESI Nasdaq
- SKYE Nasdaq
- Market Cap
- PESI 153.6M
- SKYE 172.9M
- IPO Year
- PESI 1992
- SKYE N/A
- Fundamental
- Price
- PESI $11.30
- SKYE $5.80
- Analyst Decision
- PESI Strong Buy
- SKYE Strong Buy
- Analyst Count
- PESI 1
- SKYE 5
- Target Price
- PESI $18.00
- SKYE $18.40
- AVG Volume (30 Days)
- PESI 69.2K
- SKYE 147.7K
- Earning Date
- PESI 10-31-2024
- SKYE 11-09-2024
- Dividend Yield
- PESI N/A
- SKYE N/A
- EPS Growth
- PESI N/A
- SKYE N/A
- EPS
- PESI N/A
- SKYE N/A
- Revenue
- PESI $72,199,000.00
- SKYE N/A
- Revenue This Year
- PESI N/A
- SKYE N/A
- Revenue Next Year
- PESI $52.51
- SKYE N/A
- P/E Ratio
- PESI N/A
- SKYE N/A
- Revenue Growth
- PESI N/A
- SKYE N/A
- 52 Week Low
- PESI $6.51
- SKYE $1.44
- 52 Week High
- PESI $14.17
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- PESI 58.19
- SKYE 47.89
- Support Level
- PESI $9.58
- SKYE $5.71
- Resistance Level
- PESI $10.78
- SKYE $7.11
- Average True Range (ATR)
- PESI 0.50
- SKYE 0.62
- MACD
- PESI 0.10
- SKYE 0.01
- Stochastic Oscillator
- PESI 92.23
- SKYE 7.22
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: Treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.